Transdermal Administration of Nitrates

  • Adam Schneeweiss


The original idea behind the development of transdermal delivery systems for nitrates was to avoid first-pass hepatic metabolism and to achieve constantly high plasma concentrations. The most widely used method is transdermal nitroglycerin patches. Nitroglycerin and ISDN ointments are also available. The increasing knowledge in the field has led to use of these delivery systems over less than 24 h continuously and to the development of new devices which do not provide a constant plasma level over long periods.


Angina Pectoris Isosorbide Dinitrate Chronic Congestive Heart Failure Silent Ischemia Anginal Frequency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Greco R, D’Alterio D, Schiattarella M, Boccia A, Greco L, Marsico F (1988) Efficacy of a new transdermal nitroglycerin patch (deponit 10) for stable angina pectoris. Am J Cardiol 61(9): 44E–51EPubMedCrossRefGoogle Scholar
  2. 2.
    Rezakovic DE (1985) The use of nitroglycerin patches over 6 months to treat patients with stable angina pectoris. Herz Kreislauf (Suppl 2): 19–21Google Scholar
  3. 3.
    Imhof PR, Müller P, Georgopoulos AJ, Garnier B (1985) Nitroderm TTS versus oral isosorbide dinitrate. A double blind trial in patients with angina pectoris. Acta Ther 11: 155Google Scholar
  4. 4.
    James MA, Walker PR, Papouchado M, Wilkinson PR (1985) Efficacy of transdermal glyceryl trinitrate in the treatment of chronic stable angina pectoris. Br Heart J 63: 631–635CrossRefGoogle Scholar
  5. 5.
    Hollenberg M, Go M (1984) Clinical studies with transdermal nitroglycerin. Am Heart J 108(1): 223–231PubMedCrossRefGoogle Scholar
  6. 6.
    Muiesan G, Agabiti-Rosei E, Muiesan L et al. (1986) A multicenter trial of transdermal nitroglycerin in exercise-induced angina: individual antianginal response after repeated administration. Am Heart J 112: 207–215CrossRefGoogle Scholar
  7. 7.
    Flaherty JT (1986) Usefulness of intravenous and transdermal nitroglycerin therapy in patients with unstable angina. Am Heart J 112: 220–221PubMedCrossRefGoogle Scholar
  8. 8.
    Shell WE, Kivowitz CF, Rubind SB, See J (1986) Mechanisms and therapy of silent myocardial ischemia: the effect of transdermal nitroglycerin. Am Heart J 112: 222–229PubMedCrossRefGoogle Scholar
  9. 9.
    Rajfer SL, Demme FJ, Goldberg LI (1984) Sustained beneficial hemodynamic responses to large doses of transdermal nitroglycerin in congestive heart failure and comparison with intravenous nitroglycerin. Am J Cardiol 54: 120–125PubMedCrossRefGoogle Scholar
  10. 10.
    Sharpe DN, Coxon R (1984) Nitroglycerin in a transdermal therapeutic system in chronic heart failure. J Cardiovasc Pharmacol 6: 76–82PubMedCrossRefGoogle Scholar
  11. 11.
    Armstrong PW (1987) Pharmacokinetic-hemodynamic studies of transdermal nitroglycerin in congestive heart failure. J Am Coll Cardiol 9: 420–425PubMedCrossRefGoogle Scholar
  12. 12.
    Bennett ED, Davis AL (1989) A hemodynamic and pharmacokinetic study to assess a new transdermal nitroglycerin preparation in normal subjects. Eur J Clin Pharmacol (in press)Google Scholar
  13. 13.
    Schaer DH, Buff LA, Katz RJ (1987) Sustained nitropatch antianginal efficacy utilizing an overnight nitrate-free interval (Abstract). Circulation 76[Suppl IV]: IV–127Google Scholar
  14. 14.
    Schaer DH, Buff LA, Katz RJ (1988) Sustained antianginal efficacy of transdermal nitroglycerin patches using an overnight 10-hour nitrate free interval. Am J Cardiol 61: 46–50PubMedCrossRefGoogle Scholar
  15. 15.
    Reiniger G, Rudolph W (1987) Discontinuous nitroglycerin release from transdermal patches: a pharmacokinetic basis for prevention of tolerance (Abstract). Circulation 76[Suppl IV]: IV–127Google Scholar
  16. 16.
    Charash B, Scheidt SS (1986) The controversy over transdermal nitroglycerin: an update. Am Heart J 112: 207–215PubMedCrossRefGoogle Scholar
  17. 17.
    Parker JO, Fung H-L (1984) Transdermal nitroglycerin in angina pectoris. Am J Cardiol 54: 471–476PubMedCrossRefGoogle Scholar
  18. 18.
    Sullivan M, Savvides M, Abouantoun S, Birk-Madsen E, Froelicher V (1985) Failure of transdermal nitroglycerin to improve exercise capacity in patients with angina pectoris. J Am Coll Cardiol 5: 1220–1223PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • Adam Schneeweiss
    • 1
  1. 1.Tel AvivIsrael

Personalised recommendations